The FDA approved the PD-1 inhibitor penpulimab, with two indications, for treating non-keratinizing nasopharyngeal carcinoma ...

The FDA has approved penpulimab-kcqx with chemotherapy and as a single agent for some patients with nasopharyngeal carcinoma.

4月15日，一附院普通外科李徐奇教授团队在国际顶级医学期刊《英国医学杂志》（The BMJ，影响因子93.6），发表题为《鼻咽癌诱导化疗：局部晚期疾病的新治疗选择》(Induction chemotherapy for nasopharyngeal ...

On April 23, 2025, the U.S. Food and Drug Administration (FDA) granted approval to Akeso Biopharma Co., Ltd.’s penpulimab-kcqx for the first-line treatment of adults with recurrent or metastatic ...

Persistent Epstein-Barr virus DNA or its resurgence during treatment was associated with worse survival in patients with ...

State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer Nasopharyngeal carcinoma (NPC) is a unique head and neck cancer, where the endemic subtype ...

therapy in combination with radiotherapy is an effective treatment for late-stage nasopharyngeal carcinoma (NPC). The authors conclude that radiotherapy combined with intratumoral administration ...

A collaborative study published on January 21 in Nature Communications presents a novel strategy to improve the effectiveness of radiotherapy for nasopharyngeal carcinoma (NPC). The study ...

in India under the brand name Zytorvi for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a rare form of head and neck cancer. Loqtorzi, a novel anti-PD-1 ...